These genetic alterations critically affect the clinical and pathological characteristics of thyroid cancer by activating the mitogen activated protein kinase (MAPK) and/or PI3K/AKT/mTOR signaling pathways. The gene discussed is AKT1; the disease is thyroid gland carcinoma.